Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Trial Profile

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Coronary disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DECLARE; DECLARE-TIMI58
  • Sponsors AstraZeneca
  • Most Recent Events

    • 13 Jun 2017 Trial design and baseline characteristics presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 08 Jun 2017 According to an AstraZeneca media release, trial design and baseline characteristics will be presented at the American Diabetes Associations (ADA) 77th Scientific Sessions.
    • 19 Mar 2017 According to an AstraZeneca media release, data from this trial are expected in 2019 at the latest.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top